Skip to main content
Premium Trial:

Request an Annual Quote

Genencor, Brain in Metagenomic Collaboration

NEW YORK (GenomeWeb News) — German biotech company Brain AG and Genencor will collaborate to use metagenomics and metabolic pathway engineering to develop enzymes and biosynthetic pathways for use in developing products that could be used to replace petrochemicals in products such as biofuels, plastics, rubber, adhesives, and cosmetics, Genencor said today.
Genencor, which is a division of Danisco, said it will combine its metabolic engineering and bio-manufacturing with Brain’s metagenomic and screening technologies to produce products. Genencor said Brain’s metagenomic resources include around 150 million genes from “yet uncultured organisms.”
“Brain’s capabilities and expertise in metagenomic enzyme discovery fits nicely within our model for open innovation where we look to make the transition from bench to market more effective and efficient,” Karl Sanford, VP of technology development at Genencor, said in a statement.
This collaboration expands on an earlier one from 2004, in which the two companies worked together to develop a new enzyme product platform.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.